Initial clinical experience with regadenoson, a novel selective A 2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging

89Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

OBJECTIVES: Regadenoson, a selective A2A adenosine receptor agonist, was evaluated for tolerability and effectiveness as a pharmacological stress agent for detecting reversible myocardial hypoperfusion when combined with single-photon emission computed tomography (SPECT). BACKGROUND: Adenosine and dipyridamole are nonselective adenosine agonists currently used as pharmacologic stressors. Despite proven safety, these agents often cause undesirable side effects and require a continuous infusion. METHODS: This Phase II, multicenter, open-label trial was conducted in 36 patients who had demonstrated ischemia on a 6-min adenosine SPECT imaging study within the previous 2 to 46 days. Patients received regadenoson as a rapid intravenous bolus dose of 400 μg (n = 18) or 500 μg (n = 18). The radiopharmaceutical was then delivered within one minute. The SPECT images were acquired in a standard manner and uniformly processed at a central laboratory. Regadenoson and adenosine studies were presented in random order and interpreted blindly with a 17-segment model by three observers. Additionally, quantitative analysis was performed with 4D-MSPECT software (University of Michigan, Ann Arbor, Michigan). RESULTS: Overall agreement for the presence of reversible hypoperfusion was 86%. The 400-μg dose was better tolerated. Overall, regadenoson was well-tolerated; side effects (e.g., chest discomfort, flushing, dyspnea) were generally mild in severity and self-limiting. High-grade atrioventricular block and bronchospasm were not observed. CONCLUSIONS: Regadenoson is well-tolerated and seems as effective as adenosine for detecting and quantifying the extent of hypoperfusion observed with SPECT perfusion imaging. Phase III clinical trials are now underway, given the promise of regadenoson's reduced side effects and simplicity of bolus administration. © 2005 by the American College of Cardiology Foundation.

Cite

CITATION STYLE

APA

Hendel, R. C., Bateman, T. M., Cerqueira, M. D., Iskandrian, A. E., Leppo, J. A., Blackburn, B., & Mahmarian, J. J. (2005). Initial clinical experience with regadenoson, a novel selective A 2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. Journal of the American College of Cardiology, 46(11), 2069–2075. https://doi.org/10.1016/j.jacc.2005.05.097

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free